Recent advances in medicinal chemistry of sulfonamides. rational design as anti-tumoral, anti-bacterial and anti-inflammatory agents

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 70-86

  Shah, Syed Shoaib Ahmad ^a   Rivera, Gildardo ^b   Ashfaq, Muhammad ^a  

^a THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Anti bacterial; Anti inflammatory; Anti tumoral; Biological activity; Clinical use; Structure activity relationship; Sulfonamide

Indexed keywords

4 (2 OXOIMIDAZOLIDIN 1 YL) N PHENYL BENZENE SULFONAMIDE DERIVATIVE; 4 (2 OXOIMIDAZOLIDIN 1 YL)BENZENESULFONATE; 4 METHYL 3 (PYRIMIDIN 2 YLAMINO) BENZENE SULFONAMIDE; 7H [1,3,4]THIDIAZOLO [3,2 ALPHA] PYRIMIDINE 2 SULFONAMIDE DERIVATIVE; ACETAZOLAMIDE; AZD 5438; AZITHROMYCIN; BENZOTHIAZINE DERIVATIVE; CARBONATE DEHYDRATASE INHIBITOR; CHLORAMINE B; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLIN DEPENDENT KINASE; DICLOFENAMIDE; DOXORUBICIN; ETHOXZOLAMIDE; FLUCONAZOLE; FLUOROURACIL; IMIDAZO[1,2-A]PYRIDINE DERIVATIVE; IMIPENEM; INDISULAM; MEROPENEM; METHAZOLAMIDE; NORFLOXACIN; PHENYL 4 (2 OXOIMIDAZOLIDIN 1 YL) BENZENESULFONAMIDE; PHENYLBUTAZONE; QUINOLINE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DIVISION; CELL PROLIFERATION; CYTOTOXICITY; DRUG POTENCY; GAMMA RADIATION; HODGKIN DISEASE; HUMAN; IC 50; NEOPLASM; NONHUMAN; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CARCINOMA;

EID: 84875021547     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955713804484749     Document Type: Article

References (69)

1. Camargo-Ordoñez, A.; Moreno-Reyes, C.; Olazarán-Santibáñez, F.; Martínez-Hernández, S.; Bocanegra-García, V.; Rivera, G. Efficient synthesis of sulfonamide derivatives on solid supports catalyzed using solvent-free and microwave-assisted methods. Quim. Nova, 2011, 34, 787-791.
2. Ali, A.; Reddy, G.S.K.K.; Cao, H.; Anjum, S.G.; Nalam, M.N. L.; Schiffer, C.A.; Rana, T.M. Discovery of HIV-1 Protease Inhibitors with Picomolar Affinities Incorporating N-Aryl-oxazolidinone-5-carboxamides as Novel P2 Ligands. J. Med. Chem., 2006, 49, 7342-7356.
3. McCarroll, A.J.; Bradshaw, T.D.; Westwell, A.D.; Matthews, C.S.; Stevens, M.F.G. Quinols as novel therapeutic agents. 7.1 Synthesis of antitumor 4-[1-(arylsulfonyl-1H-indol-2-yl)]-4-hydroxycyclohexa-2,5-dien-1-ones by Sonogashira reactions. J. Med. Chem., 2007, 50, 1707-1710.
4. Wilkinson, B.L.; Bomaghi, L.F.; Houston, T.A.; Innocenti, A.; Vullo, D.; Supuran C.T.; Poulsen, S.A. Carbonic Anhydrase Inhibitors: Inhibition of Isozymes I, II, and IX with Triazole-Linked O-Glycosides of Benzene Sulfonamides. J. Med. Chem., 2007, 50, 1651-1657.
5. Drews, J. Drug Discovery: A Historical Perspective. Science, 2000, 287, 1960-1964.
6. Boyd, A.E. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes, 1988, 37, 847-850.
7. Supuran, C.T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents, 2000, 10, 575-600.
8. Kadi, A.A.; El-Brollosy, N.R.; Al-Deeb, O.A.; Habib, E.E.; Ibrahim, T.M.; El-Emam, A.A. Synthesis, Antimicrobial, and Antiinflammatory Activities of Novel 2-(1-Adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-Adamantylamino)-5-substituted-1,3,4-thiadiazoles. Eur. J. Med. Chem., 2007, 42, 235-242.
9. Schenone, S.; Brullo, C.; Bruno, O.; Bondavalli, F.; Ranise, A.; Filippelli, W.; Rinaldi, B.; Capuano, A.; Falcone, G. New 1,3,4-thiadiazole derivatives endowed with analgesic and antiinflammatory activities. Bioorg. Med. Chem., 2006, 14, 1698-1705.
10. Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; El-Hazek, R.M. Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety. Eur. J. Med. Chem., 2011, 46, 5120-5126.
11. Liou, J.P.; Hsu, K.S.; Kuo, C.C.; Chang, C.Y.; Chang, J.Y. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. JPET, 2007, 323, 398-405.
12. Chen, Z.; Xu, W.; Liu, K.; Yang, S.; Fan, H.; Bhadury, P.S.; Hu, D.Y.; Zhang, Y. Synthesis and Antiviral Activity of 5-(4-Chlorophenyl)-1,3,4-Thiadiazole Sulfonamides. Molecules, 2010, 15, 9046-9056.
13. Scozzafava, A.; Owa, T.; Mastrolorenzo, A.; Supuran, C.T. Anticancer and antiviral sulfonamides. Curr. Med. Chem., 2003, 10, 925-953.
14. Brun, V.; Legraverend, M.; Grierson, D.S. Cyclin-dependent kinase (CDK) inhibitors: development of a general strategy for the construction of 2,6,9-trisubstituted purine libraries. Part 3. Tetrahedron Lett., 2001, 42, 8169-8171.
15. Schang, L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. Antimicrob Chemother., 2002, 50, 779-792.
16. Sausville, E.A.; Johnson, J.; Alley, M.; Zaharevitz, D.; Senderowicz A.M. Ann. N. Y. Acad. Sci., 2000, 910, 207.
17. Ekholm, S.V.; Reed, S.I. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol., 2000, 12, 676-684.
18. Davies, T.G.; Tunnah, P.; Meijer, L.; Marko, D.; Eisenbrand, G.; Endicott, J.A.; Noble, M.E. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure, 2001, 9, 389-397.
19. Davies, T.G.; Pratt, D.J.; Endicott, J.A.; Johnson, L.N.; Noble, M.E. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther., 2002, 93, 125-133.
20. Byth, K.F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R.W. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther., 2009, 8, 1856-1866.
21. Byth, K.F.; Culshaw, J.D.; Green, S.; Oakes, S.E.; Thomas, A.P. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclindependent kinase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 2249-2252.
22. Babu, P.A.; Narasu, M.L.; Srinivas, K. Pyridines, pyridazines and guaninesas CDK2 inhibitors. ARKIVOC, 2007, 2, 247-265.
23. Kamal, A.; Dastagiri, D.; JanakiRamaiah, M.; Reddy, J.S.; VijayaBharathi, E.; Reddy, M.K.; PremSagar, M.V.; Reddy, T.L.; Pushpavalli, S.N.C.V.L.; Pal-Bhadra, M.; Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents. Eur. J. Med. Chem., 2011, 46, 5817-5824.
24. El-Sayed, N.S.; El-Bendary, E.R.; El-Ashry, S.M.; El-Kerdawy, M.M.; Synthesis and antitumor activity of new sulfonamide derivatives of thiadiazolo [3,2-a]pyrimidines. Eur. J. Med. Chem., 2011, 46, 3714-3720.
25. Chegwidden, W.R.; Carter, N.D.; Edwards, Y.H. (Eds.), The Carbonic Anhydrases New Horizons. Birkhäuser Verlag, Basel, Boston, Berlin., 2000.
26. Herrero, A.I.; Olmo, N. D.; Gonzalez-Escalada, J.R.; Solis, J.M. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology, 2002, 42, 210-220.
27. Stams T, Christianson DW. In: The Carbonic Anhydrases: New Horizons. Chegwidden WR, Carter ND, Edwards YH, editors. Vol. 90 Birkhäuser Verlag: Basel, Switzerland; 2000.
28. Pastorek, J.; Pastorekova, S.; Callebuant, I.; Mornon, J.P.; Zelnik, V.; Opavsky, R.; Zatovicova, M.; Liao, S.; Portetelle, D.; Stanbridge, E.J.; Zavada, J.; Burny, A.; Kattmann, R. Oncogene, 1994, 9, 2788-2888.
29. Opavsky, R.; Pastorekova, S.; Zelnik, V.; Gibadulinova, A.; Stanbridge, E.J.; Zavada, J.; Kettmann, R.; Pastorek, J. Genomics, 1996, 33, 480-487.
30. Türeci, O.; Sahin, U.; Vollmar, E.; Siemer, S.; Gottert, E.; Seitz, G.; Parkkila, A.K.; Shah, G.N.; Grubb, J.H.; Pfreundschuh, M.; Sly, W.S. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 7608-7613.
31. Innocenti, A.; Beyza Öztürk Sari{dotless}kaya, S.; Gülçin, I.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg. Med. Chem., 2010, 18, 2159-2164.
32. Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; El-Hazek, R.M. Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety. Eur. J. Med. Chem., 2011, 46, 5120-5126.
33. Fortin, S.; Wei. L.; Moreau, E.; Lacroix, J.; Côté, M-F.; Petitclerc, É.; Kotra, L.P.; Gaudreault, R.C. Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships. Eur. J. Med. Chem., 2011, 46, 5327-5342.
34. Supuran, C.T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat., 2000, 10, 575-600.
35. Supuran, C.T.; Scozzafava, A. Carbonic anhydrase inhibitors. Curr Med Chem-Imm Endoc Metab Agents, 2001, 1, 61-97.
36. Supuran, C.T.; Carbonic anhydrase inhibitors. In Carbonic Anhydrase and Modulation of Physiologic and Pathologic Processes in the Organism; I. Puscas, Ed.; Helicon: Timisoara, 1994, 29-111.
37. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293, 876-880.
38. Deininger, M.; Buchdunger, E.; Druker, BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105, 2640-2653.
39. Al-Said, M.S.; Ghorab, M.M.; Al-Dosari, M.S.; Hamed, M.M. Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety. Eur. J. Med. Chem., 2011, 46, 201-207.
40. Alqasoumi, S.I.; Al-Taweel, A.M.; Alafeefy, A.M.; Noaman, E.; Ghorab, M.M. Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents. Eur. J. Med. Chem., 2010, 45, 738-744.
41. Brzozowski, Z.; Sawinski, J.; Gdaniec, M.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives. Eur. J. Med. Chem., 2011, 46, 4403-4410.
42. Kamel, M.M.; Ali, H.I.; Anwar, M.M.; Mohamed, N.A.; Soliman, A.M. Synthesis, antitumor activity and molecular docking study of novel Sulfonamide-Schiff's bases, thiazolidinones, benzothiazinones and their C-nucleoside derivatives. Eur. J. Med. Chem., 2010, 45, 572-580.
43. Maren, T.H.; Conroy, C.W. A new class of carbonic anhydrase inhibitor. J. Biol. Chem., 1993, 268(35), 26233-26239.
44. Benfodda, Z.; Guillen, F.; Romestand, B.; Dahmani, A.; Blancou, H. Synthesis and investigation of inhibition effect of fluorinated sulfonamide derivatives on carbonic anhydrase. Eur. J. Med. Chem., 2010, 45, 1225-1229.
45. Alqasoumi, S.I.; Al-Taweel, A.M.; Alafeefy, A.M.; Ghorab, M.M.; Noaman E. Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents. Eur. J. Med. Chem., 2010, 45, 1849-1853.
46. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Koyanagi, N.; Yoshimatsu, K.; Asada, M.; Watanabe, T.; Nagasu T.; Tsukahara, K.; Iijima A.; Kitoh, K. Novel Sulfonamides as Potential Systemically Active Antitumor Agents. J. Med. Chem. 1992, 35, 2496-2497.
47. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of Action of E7010, an Orally Active Sulfonamide Antitumor Agent: Inhibition of Mitosis by Binding to the Colchicine Site of Tubulin. Cancer Res., 1997, 57, 3208-3213.
48. Koyanagi, N.; Nagasu, T.; Fujita, F.; Watanabe, T.; Tsukahara, K.; Funahashi, Y.; Fujita, M.; Taguchi, T.; Yoshino, H.; Kitoh, K. In Vivo Tumor Growth Inhibition Produced by a Novel Sulfonamide, E7010, against Rodent and Human Tumors. Cancer Res., 1994, 54, 1702-1706.
49. thNCIEORTC, Ann Oncol Suppl 7: 1996, 140.
50. Al-Said, M.S.; Ghorab, M.M.; Al-qasoumi, S.I.; El-Hossary, E.M.; Noaman, E. Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl] benzenesulfonamides. Eur. J. Med. Chem., 2010, 45, 3011-3018.
51. Brzozowski, Z.; Sawinski, J.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancerassociated isozymes IX and XII. Eur. J. Med. Chem., 2010, 45, 3656-3661.
52. Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; Arafa, R.K.; El-Hossary, E.M. In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety. Eur. J. Med. Chem., 2010, 45, 3677-3684.
53. Ghorab, M.M.; Ragab, F.A.; Hamed, M.M. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. Eur. J. Med. Chem., 2009, 44, 4211-4217.
54. Liou, J-P.; Hsu, K-S.; Kuo, C-C.; Chang, C-Y.; Chang, J-Y. A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule. JPET, 2007, 323, 398-405.
55. Kasi{dotless}mogullari{dotless}, R.; Bülbül, M.; Arslan, S.; Akgökçe, B. Synthesis, characterization and antiglaucoma activity of some novel pyrazole derivatives of 5-amino-1,3,4-thiadiazole-2-sulfonamide. Eur. J. Med. Chem., 2010, 45, 4769-4773.
56. Huang, Z.; Lin, Z.; Huang, J.; A novel kind of antitumor drugs using sulfonamide as parent compound. Eur. J. Med. Chem., 2001, 36, 863-872.
57. Zhou, C-H.; Gan, L-L.; Zhang, Y-Y.; Zhang, F-F.; Wang, G-Z.; Jin, L.; Geng, R-X. Review on supermolecules as chemical drugs. Sci. China. Ser. B Chem., 2009, 52, 415-458.
58. Brunpascaud, M.; Chau, F.; Garry, L.; Farinotti, R.; Derovin, F.; Girard, P.M. Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model. J. Acquir. Syndr. Hum. Retrovirol, 1996, 13, 201-207.
59. Wininger, D.A.; Fass, R.J. Impact of trimethoprimsulfamethoxazole prophylaxis on etiology and susceptibilities of pathogens causing human immunodeficiency virus-associated bacteremia. Antimicrob. Agents Chemother., 2002, 46, 594-597.
60. Basanagouda, M.; Shivashankar, K.; Kulkarni, M.V.; Rasal, V.; Patel, H.; Mutha, S.S.; Mohite, A.A. Synthesis and antimicrobial studies on novel sulfonamides containing 4-azidomethyl coumarin. Eur. J. Med. Chem., 2010, 45, 1151-1157.
61. Wang, X-L.; Wan, K.; Zhou, C-H. Synthesis of novel sulfanilamide-derived 1,2,3-triazoles and their evaluation for antibacterial and antifungal activities. Eur. J. Med. Chem., 2010, 45, 4631-4639.
62. Jeon, H.; Jo, N.H.; Yoo, K.H.; Choi, J-H.; Cho, H.; Cho, J-H.; Oh, C-H.; Synthesis and antibacterial evaluation of 1b-methyl-2-[5-(1-methoxyimino-2-substituted sulfonamide ethyl)pyrrolidin-3-ylthio]carbapenems and their related compounds. Eur. J. Med. Chem., 2007, 42, 358-364.
63. Kim, S.J.; Park, H.B.; Lee, J.S.; Jo, N.H.; Yoo, K.H.; Baek, D.; Kang, B-W.; Cho, J-H.; Oh, C-H. Novel lb-methylcarbapenems having cyclic sulfonamide moieties: Synthesis and evaluation of in vitro antibacterial activity. Eur. J. Med. Chem., 2007, 42, 1176-1183.
64. Iacoviello, V.R.; Zinner, S.H.; Schonfeld, W.; Kirst, H.A. (Eds.), Macrolide Antibiotics, Birkhäuser Verlag, Basel, 2002, 15-24.
65. Schonfeld, W.; Mutak, S.; in: W. Schonfeld, Kirst, H.A. (Eds.), Macrolide Antibiotics, Birkhäuser Verlag, Basel, 2002, 73-95.
66. Krajacic, M.B.; Novak, P.; Cindric, M.; Brajsa, K.; Dumic, M.; Kujundzic, N.; Azithromycine-sulfonamide conjugates as inhibitors of resistant Streptococcus pyogenes strains. Eur. J. Med. Chem., 2007, 42, 138-145.
67. Gadad, A.K.; Mahajanshetti, C.S.; Nimbalkar, S.; Raichurkar, A. Synthesis and antibacterial activity of some 5-guanylhydrazone/ thiocyanato-6-arylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide derivatives. Eur. J. Med. Chem., 2000, 35, 853-857.
68. Bano, S.; Javed, K.; Ahmad, S.; Rathish, I.G.; Singh, S.; Alam, M.S. Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents. Eur. J. Med. Chem., 2011, 46, 5763-5768.
69. Sondhi, S.M.; Dinodia, M.; Jain, S.; Kumar, A. Synthesis of biologically active N-methyl derivatives of amidines and cyclized five-membered products of amidines with oxalyl chloride. Eur. J. Med. Chem., 2008, 43, 2824-2830.